A carregar...
Counting the cost of caplacizumab
In this issue of Blood, Goshua et al present a timely cost-effectiveness analysis of caplacizumab for immune thrombotic thrombocytopenic purpura (iTTP) and conclude that adding caplacizumab to standard-of-care (SOC) therapy with plasma exchange and immunosuppression is not cost-effective based on ou...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918185/ https://ncbi.nlm.nih.gov/pubmed/33599760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009250 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|